Published in Obesity and Diabetes Week, January 30th, 2006
Under the expanded agreement, Chromos will use its ACE System to develop a cell line for a Pfizer therapeutic protein product candidate. The parties will also initiate a collaborative program to genetically engineer production cell lines.
"Our relationship with Pfizer has been exceptionally productive as evidenced by their expanded commitment to the ACE System," said Alistair Duncan, president and CEO of Chromos. "We look forward to continuing to work on multiple programs with Pfizer to take advantage of the unique features and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.